Embody vs MEDVi: Which GLP-1 Provider Is Better?
Short answer: Embody and MEDVi tie at 7.3/10 on our rubric, so the decision comes down to price and format rather than overall quality. Full reasoning, pricing and the cases where the other one wins are below.
Embody publishes the lower starting rates in this matchup: compounded injections from $69/mo and GLP-1 + GIP injections from $129/mo on selected multi-week plans, compared with MEDVi's $179 semaglutide first month and $299 refill rate. MEDVi offers more formats and has the higher Trustpilot rating at 4.4/5, but both companies have F ratings at the BBB and MEDVi received FDA warning letter #721455.
Disclosure: Embody and MEDVi both pay us a commission when you sign up through our links. Neither commission changes the prices, customer records, FDA record or which provider wins a section below. How we make money.
A side-by-side look at Embody and MEDVi to help you decide. We compare them on:
- •Starting price per month
- •Our overall score, out of 10
- •Medication type, brand-name or compounded
- •Whether they accept insurance
- •Who each one is best for
Embody
#32 of 54Online weight-loss program that ships compounded GLP-1 medication to your door. Modern Metabolic Medicine, Inc. runs the storefront and OpenLoop Health supplies the clinical network on the current site. Embody now advertises compounded semaglutide from $79 and GLP-1 + GIP from $129; its FAQ says the chosen rate holds within a selected 4-, 12-, 24- or 52-week plan. Its standout is oral tirzepatide gum for people who do not want injections.
Visit EmbodyMEDVi
#46 of 54MEDVi offers oral and injectable compounded GLP-1 care. Semaglutide is $179 for month one and $299 for refills. Trustpilot is 4.4/5 across roughly 11,000 reviews, while BBB is F/not accredited. FDA warning letter #721455 concerns misleading labeling and marketing, not an allegation that the medication was unsafe.
Visit MEDVi| Feature | Embody | MEDVi |
|---|---|---|
| Why each one | One of the few GLP-1 providers offering oral tirzepatide as a chewable gum, a real choice for people who don't want injections. | Oral and injectable compounded formats in one program, with micro-dosing options and a path to FDA-approved brand medication. |
| Our Score | 7.3/10 | 5.7/10 |
| Headline Price | from $69/mo | $179 first month, then $299/mo |
| Medication Type | Compounded | Both |
| Insurance Accepted | No | No |
| Best For | People who want the oral tirzepatide gum, or who are comfortable selecting a 4-, 12-, 24- or 52-week plan for an advertised GLP-1 + GIP rate from $129 | Users who want both oral and injectable compounded options in one telehealth program |
| Watch out for | Runs two sibling storefronts most shoppers will never connect to it: SnagRx (snagrx.com) and RodeoMeds (rodeomeds.com) are the same legal entity, Modern Metabolic Medicine, Inc. SnagRx still advertises a separate $69/$119 promotion; Embody now advertises $79/$129 under its own plan menu. Neither site tells shoppers they share an operator. See our [SnagRx review](/reviews/snagrx) | FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication |
| Ranking | #32 | #46 |
| Get started | Visit Embody | Visit MEDVi |
Pros & Cons Compared
Embody
Pros
- +Oral tirzepatide gum is rare. Real option for needle-phobic users. (How well it absorbs vs the FDA-approved injection isn't published.)
- +Advertised injection floors of $79 for semaglutide and $129 for GLP-1 + GIP, verified August 14, 2026. The FAQ says the selected rate holds within the chosen plan.
- +Four plan lengths are disclosed (4, 12, 24 and 52 weeks), giving shoppers a shorter-term option as well as longer-plan pricing.
- +100% money-back guarantee in writing: if you follow the program and don't see results in 6 months, they say they'll make it right.
- +Replies to every negative Trustpilot review, usually within 24 hours.
Cons
- −Runs two sibling storefronts most shoppers will never connect to it: SnagRx (snagrx.com) and RodeoMeds (rodeomeds.com) are the same legal entity, Modern Metabolic Medicine, Inc. SnagRx still advertises a separate $69/$119 promotion; Embody now advertises $79/$129 under its own plan menu. Neither site tells shoppers they share an operator. See our [SnagRx review](/reviews/snagrx)
- −The $79/$129 figures are advertised floors tied to a selected 4-, 12-, 24- or 52-week plan, not a verified no-commitment month-to-month rate. Confirm the plan length and total before payment.
- −Trustpilot rating is 3.8 / 5 across 5,305 reviews, verified August 14, 2026. Price and billing remain recurring complaint themes, although many reviews describe earlier pricing structures.
- −Embody names four pharmacy partners: RedRock Pharmacy, Health Warehouse, Precision Compounding and Triad Rx. It does not state whether each prescription is filled through a 503A pharmacy or a 503B outsourcing facility. Triad Rx received a 2019 FDA warning letter for sterile-production violations; FDA closed it out in May 2023.
- −No HIPAA disclosure on their site (HIPAA is the federal law protecting your medical info, most telehealth providers publish a statement confirming they follow it).
- −Compounded medications only, no brand-name Wegovy, Zepbound, Mounjaro, or Ozempic available.
- −If you stop treatment and come back, Embody's doctors will likely restart you at the lowest dose (2.5mg). It's their safety policy; raise your dose history at signup, the prescriber makes the final call.
MEDVi
Pros
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179 covers the first month of compounded semaglutide on the current Katalys landing, including clinician review, medication and shipping
Cons
- −FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication
- −Its third-party records conflict: 4.4/5 across roughly 11,000 Trustpilot reviews, but an F and no accreditation at the BBB
- −The $179 semaglutide price is introductory; the current Katalys landing says refills are $299/mo, making the first-year total $3,468 rather than $2,148
- −Brand-name Wegovy and Zepbound paths add a $99 membership plus the medication cost, which the current landing does not publish; availability can change
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Where Embody wins on price
Embody advertises compounded injections from $69/mo and GLP-1 + GIP injections from $129/mo. Its FAQ ties the rate to a selected 4-, 12-, 24- or 52-week plan, so those are plan-dependent starting prices rather than proof of a flat, no-commitment monthly rate. MEDVi's current Katalys destination lists compounded semaglutide at $179 for month one and $299 for refills. Embody therefore publishes the lower floor, but a defensible total requires the exact medication and plan term at checkout.
The trade-off is choice. Embody's menu is compounded semaglutide, compounded tirzepatide and oral tirzepatide gum. MEDVi lists oral and injectable compounded formats plus brand-name Wegovy, Zepbound and Ozempic paths, although the current landing does not publish an all-in medication cost for those brand options.
Sources: Current Embody offer (affiliate link) · Current MEDVi offer (affiliate link)
Where MEDVi wins on formats and customer ratings
MEDVi offers more ways to take treatment. It lists oral tablets and injections for compounded GLP-1 care, while Embody's unusual non-injection option is tirzepatide gum. Both now name pharmacy partners: MEDVi lists RedRock Pharmacy and Beaker Pharmacy & Compounding; Embody lists RedRock, Health Warehouse, Precision Compounding and Triad Rx.
MEDVi's verified Trustpilot signal is stronger: 4.4/5 across roughly 11,000 reviews against Embody's 3.8/5 across 5,305 on August 14, 2026. Do not read either number alone. Both businesses have unaccredited F ratings at the BBB; Embody's operator had 23 complaints recorded as unanswered, while its older Trustpilot complaints often describe promotional pricing that differs from the current plan-dependent offer.
Sources: MEDVi on Trustpilot · MEDVi at the BBB · Embody on Trustpilot
What the FDA record changes
The FDA issued warning letter #721455 to MEDVi on February 20, 2026. The agency says MEDVi-branded labels implied MEDVi compounded the products when it did not, and that website comparisons implied compounded semaglutide and tirzepatide were equivalent to or FDA-evaluated like approved brands. This is a misbranding and marketing action, not an allegation that the medication was unsafe.
Our published rubric applies the same 2.0-point penalty when an FDA warning letter has no public close-out record. No public close-out letter for MEDVi was found as of August 14, 2026, so MEDVi moves from its 7.7 base score to 5.7. MEDVi gets no scoring exception because it is an affiliate partner.
Sources: FDA warning letter #721455 · Our scoring methodology
Embody vs MEDVi: common questions
Is Embody or MEDVi cheaper?
Embody publishes the lower starting rates: compounded injections from $69/mo and GLP-1 + GIP injections from $129/mo, compared with MEDVi's $179 semaglutide first month and $299 refills. Embody ties its advertised rates to a selected plan length, so compare the exact medication and commitment at checkout rather than treating either floor as a universal annual total.
Does Embody or MEDVi have better reviews?
MEDVi has the higher verified Trustpilot rating, 4.4/5 across roughly 11,000 reviews versus Embody at 3.8/5 across 5,305 on August 14, 2026. Both have F, non-accredited BBB profiles, so the honest answer is that their review and complaint signals are mixed rather than clean endorsements.
Is Embody or MEDVi safer?
We cannot prove one provider's medication is safer from public records alone. We can compare the regulatory and disclosure record: MEDVi received FDA warning letter #721455 for misleading labeling and marketing, while no FDA warning letter is recorded for Embody in our current safety database. The MEDVi letter does not allege unsafe medication. MEDVi names two pharmacy partners and Embody names four; neither disclosure proves medication quality by itself.
Should I choose Embody or MEDVi?
Consider Embody first if the lower advertised plan rate fits your medication and commitment. Consider MEDVi if you specifically need its oral tablet formats or brand-name paths and are comfortable with the $179-to-$299 price step, BBB F and FDA warning record. Both pay us a commission, so affiliate status does not break the tie.
Read Full Reviews
Related comparisons
More head-to-head comparisons involving Embody and MEDVi.
- Embody vs Sprout Health$199 first month, then $249/mo
- Embody vs Enhance MDfrom $212/mo
- Embody vs bmiMD$289/mo month-to-month
- MEDVi vs Wellorithmfrom $147/mo
- MEDVi vs SkinnyRxfrom $199/mo
- MEDVi vs Bodybuilding Health+from $179/mo
Not sure which one is right for you?
Answer a few quick questions and we'll match you to the best GLP-1 provider for your needs. Or keep exploring below.